Sage Therapeutics Q3 2024 GAAP EPS $(1.53) Misses $(1.52) Estimate, Sales $11.871M Beat $10.802M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics reported a Q3 2024 GAAP EPS of $(1.53), missing the estimate of $(1.52). However, sales were $11.871M, beating the $10.802M estimate and showing a 337.08% increase from the previous year.

October 29, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sage Therapeutics reported a Q3 2024 EPS of $(1.53), slightly missing estimates, but sales of $11.871M exceeded expectations and grew significantly year-over-year.
The EPS miss is minor, but the significant sales beat and year-over-year growth are positive indicators. The mixed results may lead to neutral short-term stock movement as investors weigh the EPS miss against strong sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100